Comparison of fesoterodine and mirabegron in the treatment of female overactive baldder patients with urgency incontinence: A randomized, prospective study (Feminine study)

Comparison of fesoterodine and mirabegron in the treatment of female overactive baldder patients with urgency incontinence: A randomized, prospective study (Feminine study) - Feminine study

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024442

Enrollment

300

Registered

2016-11-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

the intervention of fesoterodine as the treatment of overactive bladder the intervention of mirabegron as the treatment of overactive bladderor

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: total OAB symptom scores (OABSS) of >3, urgency incontinece episodes >1 per week, post-menopausal women, and age >50 years.

Exclusion criteria

Exclusion criteria: Patients were excluded if they received oral anticholinergic agents, alpha1-blockers, antidepressants, or anti-anxiety agents, had obvious neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection, or had severe cardiac disease, renal dysfunction (serum-creatinine >2 mg/dL), and/or hepatic dysfunction (i.e., aspartate aminotransferase and alanine aminotransferase levels of more than twice the normal value)

Design outcomes

Primary

Measure	Time frame
the change of urgency incontinence between fesoterodine and mirabegron	—

Secondary

Measure	Time frame
the change of CLSS, OABSS, OAB-q, and ICIQ-SF	—

Countries

Japan

Contacts

Public ContactYoshihisa Matsukawa

Nagoya University Graduate School of Medicine Department of urology

yoshi44@med.nagoya-u.ac.jp052-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026